A detailed history of Darwin Global Management, Ltd. transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Darwin Global Management, Ltd. holds 1,523,732 shares of KROS stock, worth $25.9 Million. This represents 7.2% of its overall portfolio holdings.

Number of Shares
1,523,732
Previous 1,525,902 0.14%
Holding current value
$25.9 Million
Previous $69.7 Million 26.89%
% of portfolio
7.2%
Previous 8.43%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$41.68 - $58.07 $90,445 - $126,011
-2,170 Reduced 0.14%
1,523,732 $88.5 Million
Q2 2024

Aug 14, 2024

BUY
$44.58 - $66.89 $4.01 Million - $6.02 Million
89,952 Added 6.26%
1,525,902 $69.7 Million
Q1 2024

May 15, 2024

BUY
$41.26 - $70.48 $15.5 Million - $26.5 Million
375,523 Added 35.41%
1,435,950 $95.1 Million
Q4 2023

Feb 14, 2024

BUY
$27.12 - $41.05 $28.8 Million - $43.5 Million
1,060,427 New
1,060,427 $42.2 Million
Q1 2023

May 15, 2023

SELL
$41.44 - $59.32 $16.5 Million - $23.6 Million
-397,146 Reduced 92.68%
31,386 $1.34 Million
Q4 2022

Feb 14, 2023

BUY
$39.45 - $51.77 $16.9 Million - $22.2 Million
428,532 New
428,532 $20.6 Million
Q1 2022

May 16, 2022

SELL
$42.12 - $59.36 $4.7 Million - $6.62 Million
-111,500 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$36.95 - $62.89 $4.12 Million - $7.01 Million
111,500 New
111,500 $6.52 Million
Q3 2021

Nov 15, 2021

SELL
$29.27 - $43.71 $3.05 Million - $4.55 Million
-104,186 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$42.4 - $70.11 $733,477 - $1.21 Million
17,299 Added 19.91%
104,186 $4.43 Million
Q1 2021

May 17, 2021

BUY
$54.0 - $75.28 $4.69 Million - $6.54 Million
86,887 New
86,887 $5.35 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $439M
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Darwin Global Management, Ltd. Portfolio

Follow Darwin Global Management, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Darwin Global Management, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Darwin Global Management, Ltd. with notifications on news.